NASDAQ:GRNA GreenLight Biosciences (GRNA) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free GRNA Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3050-Day Range$0.30▼$0.3052-Week Range$0.18▼$5.90Volume732 shsAverage Volume486,986 shsMarket Capitalization$45.43 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get GreenLight Biosciences alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About GreenLight Biosciences Stock (NASDAQ:GRNA)FUNR manufactures and sells all-natural juice beverages. Its products include pomegranate cranberry, wild berry and passion fruit-orange. The company was founded by Alex C. Procopio on July 22, 1980 and is headquartered in Las Vegas, NV.Read More Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… GRNA Stock News HeadlinesDecember 20, 2023 | bbc.comSplashdown Quaywest gets green light for £3m upgradeSeptember 28, 2023 | bbc.comBroadwalk Shopping Centre redevelopment given green lightMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.September 19, 2023 | forbes.comGreenlight Family Cash Card 2023 ReviewJuly 24, 2023 | finanznachrichten.deGreenLight Biosciences: GreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 24, 2023 | finance.yahoo.comGreenLight Announces Completion of Merger with Fall Line Endurance FundJuly 20, 2023 | finance.yahoo.comGreenLight Biosciences Announces Expiration of Tender Offer Period for Outstanding SharesJune 13, 2023 | bizjournals.comRNA company to lay off 96 employees in LexingtonMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.June 5, 2023 | benzinga.comGRNA ALERT: Levi & Korsinsky, LLP Announces an Investigation of Greenlight BiosciencesJune 1, 2023 | bizjournals.comRTP biotech went public a year ago. Now, it's being acquiredJune 1, 2023 | bizjournals.comThe Petri Dish: GreenLight to go private; C4 licenses cancer drug for $392MMay 31, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating GreenLight Biosciences Holdings BuyoutMay 30, 2023 | benzinga.comShareholder Alert: Ademi LLP investigates whether GreenLight Biosciences Holdings, PBC has obtained a Fair Price in its transaction with Fall LineMay 30, 2023 | msn.comGreenLight Biosciences trades 36% higher on merger agreement with Fall Line Endurance FundMay 30, 2023 | finance.yahoo.comGreenLight Biosciences Enters into Definitive Merger Agreement with Consortium Led by Fall Line Endurance Fund for Go-Private TransactionMay 12, 2023 | msn.comRecap: GreenLight Biosciences Q1 EarningsMay 12, 2023 | msn.comGreenLight Biosciences GAAP EPS of -$0.19 beats by $0.08, revenue of $3.82M beats by $3.32MMay 11, 2023 | finance.yahoo.comGreenLight Biosciences Announces First Quarter 2023 Financial Results and Highlights Recent Company ProgressApril 12, 2023 | finance.yahoo.comGreenLight Biosciences Releases Inaugural Sustainability ReportApril 1, 2023 | seekingalpha.comGreenLight Biosciences draws private equity interest; up 10%March 30, 2023 | finance.yahoo.comGreenLight Biosciences Holdings Confirms Receipt of Indication of Interest from Fall LineMarch 28, 2023 | finance.yahoo.comGreenLight Biosciences Announces Fourth Quarter and Full Year 2022 Financial ResultsMarch 9, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Human Health R&D DayMarch 7, 2023 | finance.yahoo.comGreenLight Biosciences Outlines Development Strategy and Highlights Portfolio Updates at Plant Health R&D DayMarch 4, 2023 | bbc.co.ukGreenlight Screenwriting LabMarch 1, 2023 | finance.yahoo.comGreenLight Biosciences to Host R&D Day Series on Plant and Human Health Development StrategySee More Headlines Receive GRNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GreenLight Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today3/29/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:GRNA CUSIPN/A CIK1822691 Webwww.eiacorp.com Phone(760) 809-8079FaxN/AEmployees280Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.14) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,050,000.00 Net Margins-1,521.00% Pretax Margin-1,510.44% Return on Equity-374.26% Return on Assets-122.78% Debt Debt-to-Equity Ratio0.49 Current Ratio1.21 Quick Ratio1.21 Sales & Book Value Annual Sales$10.20 million Price / Sales4.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.32 per share Price / Book0.94Miscellaneous Outstanding Shares151,681,000Free Float105,722,000Market Cap$45.43 million OptionableNot Optionable Beta1.44 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for April 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesEthan ZachadnykPresident, CEO, CFO & DirectorKey CompetitorsProtara TherapeuticsNASDAQ:TARAEntera BioNASDAQ:ENTXCandel TherapeuticsNASDAQ:CADLPrecision BioSciencesNASDAQ:DTILQuince TherapeuticsNASDAQ:QNCXView All Competitors GRNA Stock Analysis - Frequently Asked Questions Should I buy or sell GreenLight Biosciences stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for GreenLight Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" GRNA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GRNA, but not buy additional shares or sell existing shares. View GRNA analyst ratings or view top-rated stocks. This page (NASDAQ:GRNA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyMost important medical advance in 100 yearsThe Oxford ClubBuy this small stock before coming AI Tidal WaveChaikin Analytics Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GreenLight Biosciences Holdings Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.